18:03 EDT Roivant Sciences jumps 15% to $13.30 after WSJ report on potential RVT-3101 sale
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- Roivant Stock (NASDAQ:ROIV) Soars on $7B Potential Sale of Colitis Drug
- Roivant rises after Bloomberg says IBD drug attracting big pharma interest
- Roivant Sciences trading resumes
- Roivant up 1% following Bloomberg report on big pharma interest in IBD drug
- Large pharma companies showing interest in Roivant IBD drug, Bloomberg says